Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance

Table 7 Change from baseline to week 12 (last-observation-carried forward) in the total brief psychiatric rating scale score and 5-factor model score

BPRS (mean ± SD)	Baseline (n = 959)	2/4 wk (n = 959)	6/8 wk (n = 959)	12 wk ± 14 d (n = 959)
Total score	43.6 ± 15.28	34.7 ± 12.22	30.1 ± 10.68	26.8 ± 9.58
Change in total score	-	-8.9 ± 9.761	-13.5 ± 12.291	-16.8 ± 13.971
Anxiety-depression	9.3 ± 4.00	7.6 ± 3.20	6.7 ± 2.75	6.0 ± 2.45
Change in anxiety-depression score	-	-1.6 ± 2.401	-2.6 ± 2.941	-3.3 ± 3.421
Anergia	8.9 ± 3.55	7.5 ± 3.01	6.7 ± 2.75	6.2 ± 2.47
Change in anergia score	-	-1.4 ± 2.281	-2.2 ± 2.691	-2.8 ± 3.001
Thought disturbance	10.7 ± 4.40	8.3 ± 3.49	7.1 ± 3.07	6.2 ± 2.79
Change in thought disturbance score	-	-2.4 ± 3.031	-3.7 ± 3.771	-4.5 ± 4.151
Activation	5.9 ± 3.10	4.7 ± 2.35	4.2 ± 1.86	3.8 ± 1.58
Change in activation score	-	-1.2 ± 2.011	-1.7 ± 2.411	-2.1 ± 2.701
Hostility-suspiciousness	8.8 ± 3.93	6.5 ± 2.85	5.4 ± 2.47	4.6 ± 2.17
Change in hostility-suspiciousness score	-	-2.3 ± 2.811	-3.4 ± 3.421	-4.1 ± 3.771

¹P < 0.001(paired t-test).

n = 959: Number of patients in the full analysis set with brief psychiatric rating scale data.